OverviewChartNewsTraderScreen

Allakos/  US01671P1003  /

IEX
2024-09-20  9:59:55 PM Chg. -0.03 Volume Bid- Ask- High Low
0.54USD -5.73% 28,965
Turnover: 15,838.80		 -Bid Size: - -Ask Size: - 0.57 0.54
GlobeNewswire 08-07 Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
GlobeNewswire 06-25 Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, wi...
GlobeNewswire 05-28 Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
GlobeNewswire 05-09 Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire 03-14 Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 02-26 Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation w...
GlobeNewswire 02-12 Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
GlobeNewswire 02-11 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - A...
GlobeNewswire 02-03 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - A...
GlobeNewswire 01-26 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - A...
GlobeNewswire 01-18 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - A...
GlobeNewswire 01-16 Allakos Announces a Restructuring to Focus on Development of AK006
GlobeNewswire 01-16 Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria...
GlobeNewswire 01-08 NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Tran...
GlobeNewswire 2023-11-13 Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire 2023-08-30 Allakos Appoints Neil Graham to its Board of Directors
GlobeNewswire 2023-08-15 An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatme...
GlobeNewswire 2022-03-01 Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
GlobeNewswire 2022-02-01 Allakos to Host Investor Day on February 15
GlobeNewswire 2021-12-22 Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS S...
GlobeNewswire 2021-11-30 Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous ...
GlobeNewswire 2021-11-08 Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results
GlobeNewswire 2021-10-24 Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the ...
GlobeNewswire 2021-08-09 Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results
GlobeNewswire 2021-06-07 Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodeniti...